Mechanisms to inhibit matrix metalloproteinase activity: Where are we in the development of clinically relevant inhibitors?

Recent Patents on Anti-Cancer Drug Discovery

Volumn 2, Issue 2, 2007, Pages 135-142

  Corbitt, Christian A ^a,b   Lin, Jing ^a,b   Lindsey, Merry L ^a,b  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b Mays Cancer Center at UT Health San Antonio   (United States)

Author keywords

Cancer; Hydroxamate; Matrix metalloproteinases; MMP inhibitors

Indexed keywords

1 [3,4 DIHYDROXY 5 (2 HYDROXYETHYL)TETRAHYDROFURAN 2 YL]PYRIMIDINE 2,4(1H,3H) DIONE; 1 [4 ETHOXY 3 (1 METHYL 7 OXO 3 PROPYL 6,7 DIHYDRO 1H PYRAZOLO[4,3 D]PYRIMIDIN 5 YLPHENYLSULFONYL) 4 METHYLPIPERAZINE]; 4 (4 PHENYLPHENOXY)BUTANOHYDROXAMIC ACID; 4 [[4 (3 AMINOPROPOXY)PHENYL]SULFONYL]TETRAHYDRO 2H PYRAN 4 CARBOXYLIC ACID 1,1 DIMETHYLETHYL ESTER; 4 DEDIMETHYLAMINOSANCYCLINE; [3 (1,3 DIOXOISOINDOLIN 2 YL) 3 (3 ETHOXY 4 METHOXYPHENYL)PROPANOYLAMINO]PROPANOATE; AE 941; ANTINEOPLASTIC AGENT; CATECHIN; CILOMILAST; CURCUMIN; DOXYCYCLINE HYCLATE; GENISTEIN; ILOMASTAT; MARIMASTAT; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE INHIBITOR; NOBILETIN; PHOSPHODIESTERASE INHIBITOR; PLACEBO; REBIMASTAT; ROLIPRAM; S 3304; SILDENAFIL; SULFONAMIDE; TADALAFIL; THEAFLAVIN; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VARDENAFIL;

CANCER; CANCER CELL; CANCER CONTROL; CANCER GROWTH; CANCER INVASION; CANCER SURVIVAL; CARCINOGENESIS; CELL PROLIFERATION; CLINICAL TRIAL; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG RESEARCH; DRUG SAFETY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG WITHDRAWAL; ENZYME ACTIVE SITE; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME INHIBITION; ENZYME LOCALIZATION; ENZYME STRUCTURE; ENZYME SUBSTRATE; ERECTILE DYSFUNCTION; HUMAN; LOW DRUG DOSE; METASTASIS POTENTIAL; MUSCULOSKELETAL DISEASE; NONHUMAN; OVERALL SURVIVAL; PATENT; PERIODONTAL DISEASE; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN TARGETING; REVIEW; SURVIVAL RATE; SURVIVAL TIME; UNSPECIFIED SIDE EFFECT;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; ENZYME INHIBITORS; HUMANS; MATRIX METALLOPROTEINASES; MOLECULAR STRUCTURE; NEOPLASMS; PATENTS AS TOPIC;

EID: 34250776006     PISSN: 15748928     EISSN: None     Source Type: Journal    
DOI: 10.2174/157489207780832423     Document Type: Review

References (96)

1. Agnantis N. Tumor markers in cancer patients. an update of their prognostic significance. Part II. In Vivo 2004; 18(4): 481-88.
2. Nagase H, Visse R, Murphy G. Structure and function of matrix metalloproteinases and TIMPs. Cardiovascular Res 2006; 69(3): 562-73.
3. Mannello F. Natural bio-drugs as matrix metalloproteinase inhibitors: New perspectives on the horizon. Rec Pat Anti-Cancer Drug Discov 2006; 191-03.
4. Murphy G, Stanton H, Cowell S, et al. Mechanism for pro matrix metalloproteinase activation. APMIS 1999; 107(1): 38-44.
5. Velasco G, Cal S, Merlos-Suarez A, et al. Human MT6-matrix metalloproteinase: identification, progelatinase A activation, and expression in brain tumors. Cancer Res 2000; 60(4): 877-82.
6. Lohi J, Wilson CL, Roby JD, et al. Epilysin, a novel human matrix metalloproteinase (MMP-28) expressed in testis and keratinocytes and in response to injury. J Biol Chem 2001; 276(13): 10134-44.
7. Marchenko GN, Strongin AY. MMP-28, a new human matrix metalloproteinase with an unusual cysteine-switch sequence is widely expressed in tumors. Gene 2001; 265(1-2): 87-93.
8. Stawowy P, Margeta C, Kallisch H, et al. Regulation of matrix metalloproteinase MT1-MMP/MMP-2 in cardiac fibroblasts by TGF-beta1 involves furin-convertase. Cardiovasc Res 2004; 63(1): 87-97.
9. Cao J, Rehemtulla A, Pavlaki M, et al. Furin directly cleaves proMMP-2 in the trans-golgi network resulting in a nonfunctioning proteinase. J Biol Chem 2005; 280(12): 10974-80.
10. Stamenkovic I. Extracellular matrix remodelling: the role of matrix metalloproteinases. J Pathol 2003; 200(4): 448-64.
11. Sternlicht M, Werb Z. How matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol 2001; 17(1): 463-516.
12. Van den Steen PE, Van Aelst I, Hvidberg V, et al. The hemopexin and Oglycosylated domains tune gelatinase B/MMP-9 bioavailability via inhibition and binding to cargo receptors. J Biol Chem 2006; 281(27): 18626-37.
13. Sawicki G, Leon H, Sawicka J, et al. Degradation of myosin light chain in isolated rat hearts subjected to ischemia-reperfusion injury: A new intracellular target for matrix metalloproteinase-2. Circulation 2005; 112(4): 544-52.
14. Velasco G, Pendas AM, Fueyo A, et al. Cloning and characterization of human MMP-23, a new matrix metalloproteinase predominantly expressed in reproductive tissues and lacking conserved domains in other family members. J Biol Chem 1999; 274(8): 4570-76.
15. Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2002; 2(3): 163-76.
16. Vu TH, Werb Z. Matrix metalloproteinases: effectors of development and normal physiology. Genes Dev 2000; 14(17): 2123-33.
17. VanSaun MN, Matrisian LM. Matrix metalloproteinases and cellular motility in development and disease. Birth Defects Res C Embryo Today 2006; 78(1): 69-79.
18. Mannello F, Tonti GAM, Bagnara GP, Stefano P. Role and function of matrix metalloproteinases in the differentiation and biological characterization of mesenchymal stem cells. Stem Cells 2006; 24(3): 475-81.
19. Lindsey ML. MMP induction and inhibition in myocardial infarction. Heart Fail Rev 2004; 9(1): 7-19.
20. Mannello F, Tønti G, Papa S. Matrix metalloproteinase inhibitors as anticancer therapeutics. Curr Cancer Drug Targets 2005; 5(4): 285-98.
21. Nelson AR, Fingleton B, Rothenberg ML, et al. Matrix metalloproteinases: biologic activity and clinical implications. J Clin Oncol 2000; 18: 1135-49.
22. Noda M, Oh J, Takahashi R, et al. RECK: a novel suppressor of malignancy linking oncogenic signaling to extracellular matrix remodeling. Cancer Metastasis Rev 2003; 22(2-3): 167-75.
23. Crawford HC, Matrisian LM. Mechanism controlling the transcription of matrix metalloproteinase genes in normal and neoplastic cells. Enzyme Protein 1996; 49(1-3): 20-37.
24. Janowska-Wieczorek A, Marquez LA, Nabholtz JM, et al. Growth factors and cytokines upregulate gelatinase expression in bone marrow CD34(+) cells and their transmigration through reconstituted basement membrane. Blood 1999; 93(10): 3379-90.
25. Ries C, Petrides PE. Cytokine regulation of matrix metalloproteinase activity and its regulatory dysfunction in disease. Biol Chem Hoppe Seyler 1995; 37: 6345-55.
26. Mauviel A. Cytokine regulation of metalloproteinase gene expression. J Cell Biochem 1993; 53: 288-95.
27. Benbow U, Brinckerhoff CE. The AP-1 Site and MMP gene regulation: what is all the fuss about? Matrix Biol 1997; 15: 519-26.
28. Goldberg GI, Maremer BL, Grant GA, et al. Human 72-kilodalton type IV collagenase forms a complex with a tissue inhibitor of metalloprotease designated TIMP-2. Proc Natl Acad Sci USA 1989; 86: 8207-11.
29. Will H, Atkinson SJ, Butler GS, et al. The soluble catalytic domain of membrane type 1 matrix metalloproteinase cleaves the propeptide of progelatinase A and initiates autoproteolytic activation. Regulation by TIMP-2 and TIMP-3. J Biol Chem 1996; 271(29): 17: 119-23.
30. Hayakawa T, Yamashita & Ohuchi E, et al. Cell growth-promoting activity of tissue inhibitor of metalloproteinases-2 (TIMP-2). J Cell Sci 1994; 107 (Pt 9): 2373-79.
31. Chang C, Werb Z. The many faces of metalloproteases: cell growth, invasion, angiogenesis and metastasis. Trends Cell Biol 2001; 11(11): S37-43.
32. Fingleton B. Matrix metalloproteinases: roles in cancer and metastasis. Front Biosci 2006; 11479-91.
33. Mott JD, Werb Z. Regulation of matrix biology by matrix metalloproteinases. Curr Opin Cell Biol 2004; 16(5): 558-64.
34. Zucker S, Cao J, Chen WT. Critical appraisal of the use of matrix metalloproteinase inhibitors in cancer treatment. Oncogene 2000; 19(56): 6642-6650.
35. Ray JM, Stetler-Stevenson WG. Gelatinase A activity directly modulates melanoma cell adhesion and spreading. EMBO 1995; 14(5): 908-17.
36. Sun WH, Sun YL, Fang RN, et al. Expression of cyclooxygenase-2 and matrix metalloproteinase-9 in gastric carcinoma and its correlation with angiogenesis. Jpn J Clin Oncol. 2005; 35(12): 707-13.
37. Sheu B-C, Hsu S-M, Ho H-N, et al. A novel role of metalloproteinase in cancer-mediated immunosuppression. Cancer Res 2001; 61(1): 237-42.
38. Porter S, Clark IM, Kevorkian L, et al. The ADAMTS metalloproteinases. Biochem J 2005; 386(Pt 1): 15-27.
39. Primakoff P, Myles DG. The ADAM gene family: surface proteins with adhesion and protease activity. Trends Genet 2000; 16(2): 83-87.
40. Saghatelian A, Jessani N, Joseph A, et al. Activity-based probes for the proteomic profiling of metalloproteases. Proc Natl Acad Sci USA 2004; 101(27): 10000-05.
41. Peterson JT. Matrix metalloproteinase inhibitor development and the remodeling of drug discovery. Heart Fail Rev 2004; 9(1): 63-79.
42. Peterson JT. The importance at estimating the therapeutic index in the development of matrix metalloproteinase inhibitors. Cardiovascular Research 2006; 69(3): 677-87.
43. Golub LM, Ciancio S, Tamamurthy NS, et al. Low-dose doxycycline therapy: Effect of gingival and crevicular fluid collagenase activity in humans. J Periodontal Res 1990; 25: 321-30.
44. Borkakoti N. Matrix metalloprotease inhibitors: design from structure. Biochem Soc Trans 2004; 32(Pt 1): 17-20.
45. Ma D, Wu W, Yang G, et al. Tetrahydroisoquinoline based sulfonamide hydroxamates as potent matrix metalloproteinase inhibitors. Bioorg Med Chem Lett 2004; 14(1): 47-50.
46. Overall CM, Kleifeld O. Towards third generation matrix metalloproteinase inhibitors for cancer therapy. Br J Cancer 2006; 94(7): 941-46.
47. Chen JM, Nelson FC, Levin JI, et al. Structure-based design of a novel, potent, and selective inhibitor for MMP-13 utilizing NMR spectroscopy and computer-aided molecular design. J. Am. Chem. Soc. 2000; 122: 9648-54.
48. Hajduk PJ, Shuker SB, Nettesheim DG, et al. NMR-based modification of matrix metalloproteinase inhibitors with improved bioavailability. J. Med. Chem. 2002; 45(26): 5628-39.
49. Sang Q-XA. Matrix metalloproteinase inhibitors as prospective agents for the prevention and treatment of cardiovascular and neoplastic diseases. Current Topics in Medicinal Chemistry 2006; 6(4): 289-316.
50. Bramhall SR, Hallissey MT, Whiting J, et al. Marimastat as maintenance therapy for patients with advanced gastric cancer: a randomised trial. Br J Cancer 2002; 86(12): 1864-70.
51. Rao BG. Recent developments in the design of specific matrix metalloproteinase inhibitors aided by structural and computational studies. Curr Pharm Des 2005; 11(3): 295-322.
52. Gingras D. Matrix proteinase inhibition by AE-941, a multifunctional antiangiogenic compound. Anticancer Res 2001; 21(1A): 145-55.
53. Fingleton B, Matrisian LM. Matrix metalloproteinases as targets for therapy in Kaposi sarcoma. Curr Opin Oncol 2001; 13(5): 368-73.
54. Lokeshwar BL, Selzer MG, Zhu B-Q, et al. Inhibition of cell proliferation, invasion, tumor growth and metastasis by an oral non-antimicrobial tetracycline analog (COL-3) in a metastatic prostate cancer model. Int J Cancer 2002; 98(2): 297-309.
55. Mant TG, Bradford D, Amin DM, et al. Pharmacokinetics and safety assessments of high-dose and 4-week treatment with S-3304, a novel matrix metalloproteinase inhibitor, in healthy volunteers. Br J Clin Pharmacol 2006; [Epub ahead of print].
56. van Marle S, van Vliet A, Sollie F, et al. Safety, tolerability and pharmacokinetics of oral S-3304, a novel matrix metalloproteinase inhibitor, in single and multiple dose escalation studies in healthy volunteers. Int J Clin Pharmacol Ther 2005; 43(6): 282-93.
57. Fisher J, Mobashery S. Recent advances in MMP inhibitor design. Cancer and Metastasis Reviews 2006; 25(1): 115-36.
58. Schafers M, Riemann B, Kopka K, et al. Scintigraphic imaging of matrix metalloproteinase activity in the arterial wall in vivo. Circulation 2004; 109(21): 2554-59.
59. Wagner S, Breyholz HJ, Faust A, et al. Molecular imaging of matrix metalloproteinases in vivo using small molecule inhibitors for SPECT and PET. Curr Med Chem 2006; 13(23): 2819-38.
60. Breyholz HJ, Schafers M, Wagner S, et al. C-5-disubstituted barbiturates as potential molecular probes for noninvasive matrix metalloproteinase imaging. J Med Chem 2005; 48(9): 3400-409.
61. Kopka K, Breyholz HJ, Wagner S, et al. Synthesis and preliminary biological evaluation of new radioiodinated MMP inhibitors for imaging MMP activity in vivo. Nucl Med Biol 2004; 31(2): 257-67.
62. Fisher J, Mobashery S. Recent advances in MMP inhibitor design. Cancer Metastasis Rev 2006; 25(1): 115-36.
63. Puerta DT, Mongan J, Tran BL, et al. Potent, selective pyrone-based inhibitors of stromelysin-1. J Am Chem Soc 2005; 127(41): 14148-49.
64. Devel L, Rogakos V, David A, et al. Development of selective inhibitors and substrate of matrix metalloproteinase-12. J Biol Chem 2006; 281(16): 11152-60.
65. Dive V, Andarawewa KL, Boulay A, et al. Dosing and scheduling influence the antitumor efficacy of a phosphinic peptide inhibitor of matrix metalloproteinases. Int J Cancer 2005; 113(5): 775-81.
66. Reiter LA, Mitchell PG, Martinelli GJ, et al. Phosphinic acid-based MMP-13 inhibitors that spare MMP-1 and MMP-3. Bioorg Med Chem Lett 2003; 13(14): 2331-36.
67. Shao ZM, Shen ZZ, Fontana JA, et al. Genistein's "ER-dependent and independent" actions are mediated through ER pathways in ER-positive breast carcinoma cell lines. Anticancer Res 2000; 20(4): 2409-416.
68. Yanagihara K, Ito A, Toge T, et al. Antiproliferative effects of isoflavones on human cancer cell lines established from the gastrointestinal tract. Cancer Res 1993; 53(23). 5815-21.
69. Rooprai HK, Kandanearatchi A, Maidment SL, et al. Evaluation of the effects of swainsonine, captopril, tangeretin and nobiletin on the biological behaviour of brain tumour cells in vitro. Neuropathol Appl Neurobiol 2001; 27(1): 29-39.
70. Huang MT, Lou YR, Xie JG, et al. Effect of dietary curcumin and dibenzoylmethane on formation of 7,12-dimethylbenz[a]anthracene-induced mammary tumors and lymphomas/leukemias in Sencar mice. Carcinogenesis 1998; 19(9): 1697-1700.
71. Cheng Y, Li HL, Wang HF, et al. Inhibition of nicotine-DNA adduct formation in mice by six dietary constituents. Food Chem Toxicol 2003; 41(7): 1045-50.
72. Freskos, J.N., Fobian, Y.M., Barta, T.E., Becker, D.P., Bedell, L.J., Boehm, T.L., Carroll, J.N., Decrescenzo, G.A., Hockerman, S.L, Kassab, D.J., Kolodziej, S.A., Mcdonald, J., Mischke, D.A., Norton, M.B., Rico, J.G., Talley, JJ., Villamil, C.I., Wing, L.J.: US2005101641 (2005).
73. Freskos JN, McDonald JJ, Mischke BV, et al. Synthesis and identification of conformationally constrained selective MMP inhibitors. Bioorg Med Chem Lett 1999; 9(13): 1757-60.
74. Freskos JN, Mischke BV, DeCrescenzo GA, et al. Discovery of a novel series of selective MMP inhibitors: identification of the gamma-sulfonethiols. Bioorg Med Chem Lett 1999; 9(7): 943-48.
75. Becker DP, Villamil CI, Barta TE, et al. Synthesis and structure-activity relationships of beta- and alpha-piperidine sulfone hydroxamic acid matrix metalloproteinase inhibitors with oral antitumor efficacy. J Med Chem 2005; 48(21): 6713-30.
76. Fesik, S.W., Summers, J.B.Jr., Davidsen, S.K., Sheppard, G.S., Steinman, D.H., Carrera, G.M.Jr., Florjancic, A., Holms, J.H.: EP0874808 (1998).
77. Fesik SW. Promoting apoptosis as a strategy for cancer drug discovery. Nat Rev Cancer 2005; 5(11): 876-85.
78. Man, H.-W., Muller, G, Huang, S.: WO0145702 (2001).
79. Muller GW, Shire MG, Wong, LM, et al. Thalidomide analogs and PDE4 inhibition. Bioorg Med Chem Lett 1998; 8(19): 2669-74.
80. Muller GW, Corral LG, Shire MG, et al. Structural modifications of thalidomide produce analogs with enhanced tumor necrosis factor inhibitory activity. J Med Chem 1996; 39(17): 3238-40.
81. Hsu, L.-W.: CN1723903 (2006).
82. Hajduk PJ, Meadows RP, Fesik SW. NMR-based screening in drug discovery. Q Rev Biophys 1999; 32(3): 211-40.
83. Summers JB, Gunn BP, Mazdiyasni H, et al. in vivo Characterization of hydroxamic acid inhibitors of 5-lipoxygenase. J Med Chem 1987; 30(11): 2121-26.
84. Summers JB, Mazdiyasni H, Holms JH, et al. Hydroxamic acid inhibitors of 5-lipoxygenase. J Med Chem 1987; 30(3): 574-80.
85. Gum RJ, Hickman D, Fagerland JA, et al. Analysis of two matrix metalloproteinase inhibitors and their metabolites for induction of phospholipidosis in rat and human hepatocytes(1). Biochem Pharmacol 2001; 62(12): 1661-73.
86. Sheppard GS, Florjancic AS, Giesler JR, et al. Aryl ketones as novel replacements for the C-terminal amide bond of succinyl hydroxamate MMP inhibitors. Bioorg Med Chem Lett 1998; 8(22): 3251-56.
87. Steinman DH, Curtin ML, Garland RB, et al. The design, synthesis, and structure-activity relationships of a series of macrocyclic MMP inhibitors. Bioorg Med Chem Lett 1998; 8(16): 2087-92.
88. Gonzalez-Cadavid NF, Rajfer J. Therapy of erectile dysfunction: potential future treatments. Endocrine 2004; 23(2-3): 167-76.
89. Rajfer J, Aronson WJ, Bush PA, et al. Nitric oxide as a mediator of relaxation of the corpus cavernosum in response to nonadrenergic, noncholinergic neurotransmission. N Engl J Med 1992; 326(2): 90-94.
90. Vernet D, Ferrini MG, Valente EG, et al. Effect of nitric oxide on the differentiation of fibroblasts into myofibroblasts in the Peyronie's fibrotic plaque and in its rat model. Nitric Oxide 2002; 7(4): 262-76.
91. Ferrini MG, Vernet D, Magee TR, et al. Antifibrotic role of inducible nitric oxide synthase. Nitric Oxide 2002; 6(3): 283-94.
92. Gonzalez-Cadavid, N., Rajfer, J.: US2005085486 (2005).
93. Oltenfreiter R, Staelens L, Labied S, et al. Tryptophane-based biphenylsulfonamide matrix metalloproteinase inhibitors as tumor imaging agents. Cancer Biother Radiopharm 2005; 20(6): 639-47.
94. Jeng AY, Chou M, Parker DT. Sulfonamide-based hydroxamic acids as potent inhibitors of mouse macrophage metalloelastase. Bioorg Med Chem Lett 1998; 8(8): 897-902.
95. Martin-Chouly CAE, Astier A, Jacob C, et al. Modulation of matrix metalloproteinase production from human lung fibroblasts by type 4 phosphodiesterase inhibitors. Life Sci 2004; 75(7): 823-40.
96. Akool E-S, Doller A, Muller R, et al. Nitric oxide induces TIMP-1 expression by activating the transforming growth factor {beta}-smad signaling pathway. J Biol Chem 2005; 280(47): 39403-416.